keyword

memantine agitation

keyword
https://read.qxmd.com/read/32285305/considerations-and-current-trends-in-the-management-of-the-geriatric-patient-on-a-consultation-liaison-service
#1
REVIEW
Oliver M Glass, Adriana P Hermida, Rachel Hershenberg, Ann C Schwartz
PURPOSE OF REVIEW: To provide consultation-liaison psychiatrists with an updated resource that can assist in the treatment and management of geriatric patients. RECENT FINDINGS: The current available literature has not shown any differences in efficacy between haloperidol and second-generation antipsychotics in patients with delirium. When considering relative advantages of forms of antipsychotic administration, there is no support for a superior safety profile of oral compared to intramuscular or intravenous administration...
April 13, 2020: Current Psychiatry Reports
https://read.qxmd.com/read/32078407/amantadine-and-memantine-a-comprehensive-review-for-acquired-brain-injury
#2
Heather M Ma, Ross D Zafonte
This comprehensive review discusses clinical studies of patients following brain injuries (traumatic, acquired, or stroke), who have been treated with amantadine or memantine. Both amantadine and memantine are commonly used in the acute rehabilitation setting following brain injuries, despite their lack of FDA-approval for neuro-recovery. Given the broad utilization of such agents, there is a need to review the evidence supporting this common off-label prescribing. The purpose of this review is to describe the mechanisms of action for memantine and amantadine, as well as to complete a comprehensive review of the clinical uses of these agents...
February 20, 2020: Brain Injury: [BI]
https://read.qxmd.com/read/31996112/the-management-of-dementia-by-flemish-gps-it-remains-a-difficult-job
#3
De Lepeleire Jan, Despriet Delfine, Van De Putte Eileen, Van Eecke Herlinde, Steyaert Jan, Schoenmakers Birgitte
Objective : The following study examines how GPs in Flanders deal with dementia in terms of detection, diagnosis, care diagnosis and treatment. Methods : An online survey was sent out by mail to 5113 Flemish GP's. Data were collected in 2016. The results were processed in a univariate and multivariate analysis with SAS 9.4 Results : 331 GPs completed the survey in full (response rate 6.47%). The results are representative of GPs of the Flemish Region in terms of distribution across the provinces and university of graduation...
January 30, 2020: Acta Clinica Belgica
https://read.qxmd.com/read/31727226/the-psychopharmacology-of-autism-spectrum-disorder-and-rett-syndrome
#4
Antonio M Persico, Arianna Ricciardello, Francesca Cucinotta
Autism spectrum disorder (ASD) appears in early childhood and is characterized by persistent deficits in communication and social interaction, as well as restricted interests, repetitive behaviors, and unusual sensory issues. ASD can be idiopathic or syndromic, in the latter case representing one of the many manifestations of a genetic disorder, such as Rett syndrome. Psychopharmacology cannot directly ameliorate core autistic symptoms, but rather aims at treating comorbid disorders, such as ADHD, sleep disturbances, psychomotor agitation and aggressiveness, seizures, and anxiety...
2019: Handbook of Clinical Neurology
https://read.qxmd.com/read/31607910/antipsychotic-treatment-of-behavioral-and-psychological-symptoms-of-dementia-bpsd-management-of-extrapyramidal-side-effects
#5
REVIEW
Yukihiro Ohno, Naofumi Kunisawa, Saki Shimizu
Antipsychotic drugs are often used for the treatment of behavioral and psychological symptoms of dementia (BPSD), especially psychosis and behavioral disturbances (e.g., aggression and agitation). They are prescribed alone or in conjunction with anti-dementia (e.g., anti-Alzheimer's disease drugs) and other psychotropic drugs (e.g., antidepressants). However, antipsychotic drugs frequently produce serious extrapyramidal side effects (EPS) including Parkinsonian symptoms (e.g., bradykinesia, akinesia, tremor, and muscle rigidity)...
2019: Frontiers in Pharmacology
https://read.qxmd.com/read/31231784/treatment-options-for-agitation-in-dementia
#6
REVIEW
John M Ringman, Lon Schneider
PURPOSE OF REVIEW: The goal of the current review is to provide an update on the management of agitation in persons with dementia with a focus on pharmacological management of persons with Alzheimer's disease. RECENT FINDINGS: As consistently effective and safe pharmacologic interventions are still lacking, identifying and addressing medical and environmental precipitants remain a priority. Acetylcholinesterase inhibitors and memantine should be initiated to enhance cognition, and if present, management of insomnia or sundowning with trazodone is indicated...
June 24, 2019: Current Treatment Options in Neurology
https://read.qxmd.com/read/30891742/memantine-for-dementia
#7
Rupert McShane, Maggie J Westby, Emmert Roberts, Neda Minakaran, Lon Schneider, Lucy E Farrimond, Nicola Maayan, Jennifer Ware, Jean Debarros
BACKGROUND: Memantine is a moderate affinity uncompetitive antagonist of glutamate NMDA receptors. It is licensed for use in moderate and severe Alzheimer's disease (AD); in the USA, it is also widely used off-label for mild AD. OBJECTIVES: To determine efficacy and safety of memantine for people with dementia. To assess whether memantine adds benefit for people already taking cholinesterase inhibitors (ChEIs). SEARCH METHODS: We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's register of trials (http://www...
March 20, 2019: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/30783429/effect-of-memantine-combined-with-citalopram-on-cognition-of-bpsd-and-moderate-alzheimer-s-disease-a-clinical-trial
#8
Tiantian Zhou, Jindong Wang, Cuiyu Xin, Lingli Kong, Chunxia Wang
Among Alzheimer's disease (AD) patients, it is very common to develop behavioral and psychological symptoms of dementia (BPSD), which has a close relation to the excess morbidity and mortality, greater healthcare use, earlier institutionalization, and caregiver burden. With evaluation of AD patients, the present study mainly aims to investigate whether citalopram would be efficient for BPSD, and examines citalopram's effects on cognitive function, caregiver distress, safety and tolerability. Eighty patients diagnosed with moderate AD and clinically significant BPSD from April 2015 to January 2016 were enrolled in this study...
March 2019: Experimental and Therapeutic Medicine
https://read.qxmd.com/read/30680679/pharmacological-management-of-dementia-with-lewy-bodies
#9
REVIEW
Linda A Hershey, Rhonda Coleman-Jackson
Dementia with Lewy bodies (DLB) is a complex disease that involves a variety of cognitive, behavioral and neurological symptoms, including progressive memory loss, visual hallucinations, parkinsonism, cognitive fluctuations and rapid eye movement sleep behavior disorder (RBD). These symptoms may appear in varying combinations and levels of severity in each patient who is seen in the clinic, making diagnosis and treatment a challenge. DLB is the third most common of all the neurodegenerative diseases behind both Alzheimer's disease and Parkinson's disease (PD)...
April 2019: Drugs & Aging
https://read.qxmd.com/read/30666436/comparative-efficacy-and-safety-of-therapy-for-the-behavioral-and-psychological-symptoms-of-dementia-a-systemic-review-and-bayesian-network-meta-analysis
#10
REVIEW
Boru Jin, Huayan Liu
OBJECTIVE: To assess the comparative efficacy and safety of both pharmacological and non-pharmacological therapies for the behavioral and psychological symptoms of dementia, using direct and indirect evidence from randomized data. METHOD: A systematic review and Bayesian network meta-analysis was conducted on only randomized controlled trials (RCTs) of all the available interventions for BPSD. RCTs were selected from Pubmed, EMBASE, the Cochrane library, and CINAHL...
January 21, 2019: Journal of Neurology
https://read.qxmd.com/read/30222469/the-efficacy-and-safety-of-memantine-for-the-treatment-of-alzheimer-s-disease
#11
REVIEW
Shinji Matsunaga, Taro Kishi, Ikuo Nomura, Kenji Sakuma, Makoto Okuya, Toshikazu Ikuta, Nakao Iwata
Currently, five pharmacotherapeutic options are available to treat Alzheimer's disease: memantine; the three cholinesterase inhibitors donepezil, galantamine, and rivastigmine; and combination treatments with memantine and one cholinesterase inhibitor. Selection of the best course of treatment is based upon the evidence gathered by systematic reviews and meta-analyses of randomized controlled trials. Areas covered: This article provides a risk-benefit analysis of these treatments using evidence from meta-analyses on their safety and their efficacy...
October 2018: Expert Opinion on Drug Safety
https://read.qxmd.com/read/30127123/evidence-for-accuracy-of-pain-assessment-and-painkillers-utilization-in-neuropsychiatric-symptoms-of-dementia-in-calabria-region-italy
#12
Damiana Scuteri, Maria Roberta Garreffa, Stefania Esposito, Giacinto Bagetta, Maria Diana Naturale, Maria Tiziana Corasaniti
During the clinical course of dementia, beside cognitive impairment and memory loss, a very complex challenge is posed by the neuropsychiatric symptoms (NPSs). Accurate evaluation and treatment of pain impacts positively the agitation of demented patients aged ≥ 65 years. To gather information on the utilization of pain killers in demented patients a preliminary survey has been conducted in collaboration with the Calabrian Pharmacovigilance Territorial Service of the health district of Catanzaro (Italy). The study has taken into consideration the prescriptions of acetylcholinesterase inhibitors and memantine during the period ranging from July 2015 to June 2016 and the percentage of patients treated against pain with non steroidal antinflammatory drugs, opioids, and anticonvulsants have been monitored...
September 2018: Neural Regeneration Research
https://read.qxmd.com/read/29966477/neuropsychiatric-symptoms-and-caregiver-burden-in-individuals-with-alzheimer-s-disease-the-team-ad-va-cooperative-study
#13
Peijun Chen, Peter D Guarino, Maurice W Dysken, Muralidhar Pallaki, Sanjay Asthana, Maria D Llorente, Susan Love, Julia E Vertrees, Gerard D Schellenberg, Mary Sano
OBJECTIVES: To assess the prevalence of neuropsychiatric symptoms (NPS) in mild-to-moderate Alzheimer disease (AD) and their association with caregiver burden. METHODS: Secondary analyses of baseline data from the Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD) (N=613). Neuropsychiatric Inventory were used to measure severity of NPS and caregiver activity survey to measure caregiver burden. RESULTS: A total of 87% of patients displayed at least 1 NPS; 70% displayed clinically meaningful NPS...
July 2018: Journal of Geriatric Psychiatry and Neurology
https://read.qxmd.com/read/29881276/memantine-induces-manic-episode-in-a-73-year-old-patient-with-vascular-neurocognitive-disorder-a-case-report
#14
Jinfeng Duan, Chengming Lao, Jingkai Chen, Fen Pan, Chenlin Zhang, Weijuan Xu, Weihua Zhou, Jianbo Hu, Desheng Shang, Manli Huang, Yi Xu
Memantine, an N -methyl-d-aspartate receptor antagonist, is a well-established treatment option for moderate-to-severe cognitive impairment related to Alzheimer disease. Recently, growing evidence has indicated memantine might also be effective in treatment of affective disorders. The common drug-induced adverse events of memantine include confusion, dizziness, drowsiness, headache, insomnia, and agitation. Herein, we presented a case of a 73-year-old female patient with vascular neurocognitive disorder, who developed a manic episode after taking memantine...
2018: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/29785112/treatment-of-behavioral-and-psychological-symptoms-of-dementias-with-psychopharmaceuticals-a-review
#15
REVIEW
Jiří Masopust, Dita Protopopová, Martin Vališ, Zbyšek Pavelek, Blanka Klímová
Behavioral and psychological symptoms represent common complications in patients with different types of dementia. Predominantly, they comprise psychosis, agitation and mood disorders, disinhibited behavior, impairment of the sleep and wakefulness rhythm, wandering, perseveration, pathological collecting, or shouting. Their appearance is related to more rapid progression of the disease, earlier institutionalization, use of physical restraints, and higher risk of mortality. Consequently, appearance of behavioral and psychological symptoms of dementia leads to higher costs of care provided and greater distress for caregivers...
2018: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/29344342/frontotemporal-dementia-latest-evidence-and-clinical-implications
#16
REVIEW
Juan Joseph Young, Mallika Lavakumar, Deena Tampi, Silpa Balachandran, Rajesh R Tampi
Background: Frontotemporal dementia (FTD) describes a cluster of neurocognitive syndromes that present with impairment of executive functioning, changes in behavior, and a decrease in language proficiency. FTD is the second most common form of dementia in those younger than 65 years and is expected to increase in prevalence as the population ages. This goal in our review is to describe advances in the understanding of neurobiological pathology, classification, assessment, and treatment of FTD syndromes...
January 2018: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/29338602/sequential-drug-treatment-algorithm-for-agitation-and-aggression-in-alzheimer-s-and-mixed-dementia
#17
Simon Jc Davies, Amer M Burhan, Donna Kim, Philip Gerretsen, Ariel Graff-Guerrero, Vincent L Woo, Sanjeev Kumar, Sarah Colman, Bruce G Pollock, Benoit H Mulsant, Tarek K Rajji
INTRODUCTION: Behavioural and psychological symptoms of dementia (BPSD) include agitation and aggression in people with dementia. BPSD is common on inpatient psychogeriatric units and may prevent individuals from living at home or in residential/nursing home settings. Several drugs and non-pharmacological treatments have been shown to be effective in reducing behavioural and psychological symptoms of dementia. Algorithmic treatment may address the challenge of synthesizing this evidence-based knowledge...
May 2018: Journal of Psychopharmacology
https://read.qxmd.com/read/28936936/-treatment-of-dementia
#18
REVIEW
K Blom, G A H van den Elsen, H L Koek, J B Sanders, H C Kruithof, J A H R Claassen
- Treatment options for patients with dementia are limited. This article provides an overview of possible interventions, both pharmaceutical and non-pharmaceutical, for Alzheimer's disease, vascular dementia and mixed dementia.- Pharmaceutical treatment options include cholinesterase inhibitors, memantine and experimental medication. Cholinesterase inhibitors are only recommended for Alzheimer's disease and mixed dementia, not for vascular dementia or mild cognitive impairment. There is no proof of effectiveness for the other pharmaceutical options...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://read.qxmd.com/read/28790827/the-effects-of-memantine-on-behavioral-disturbances-in-patients-with-alzheimer-s-disease-a-meta-analysis
#19
Taro Kishi, Shinji Matsunaga, Nakao Iwata
BACKGROUND: Memantine is effective in the treatment of behavioral disturbances in patients with Alzheimer's disease. It has not yet been fully determined which behavioral disturbances respond best to memantine. METHODS: We conducted a meta-analysis of memantine vs control (placebo or usual care) for the treatment of individual behavioral disturbances (delusion, hallucination, agitation/aggression, dysphoria, anxiety/phobia, euphoria, apathy, disinhibition, irritability/lability, aberrant motor activity/activity disturbances, nighttime disturbance/diurnal rhythm disturbances, and eating disturbances)...
2017: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/28763881/-efficacy-and-tolerance-of-memantine-monotherapy-and-combination-therapy-with-reinhartdt-and-sea-cucumber-capsule-on-agitation-in-moderate-to-severe-alzheimer-disease
#20
E Y Yu, Z L Liao, Y F Tan, Y J Qiu, J P Zhu, Y Chen, S S Lin, M H Wu
Objective: To explore the efficacy and tolerance of Memantine combined Reinhartdt And Sea Cucumber Capsule (R.S.C) on treating agitation in patients with moderate-severe Alzheimer disease (AD). Methods: One hundred and fifty-eight moderate-sever AD patients from Sep.2013 to Sep.2014 in Zhejiang Provincial People's Hospital were randomly divided into two groups: group of Memantine combined R. S.C and group of single Memantine. Then Mini-Mental Sate Examination (MMSE) and Neuropsychiatric Inventory (NPI) were used to evaluate cognition symptom, behavioral and psychological symptoms of dementia (BPSD) and agitation symptom at the baseline and the end of 24 weeks...
July 18, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
keyword
keyword
81574
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"